Researchers have developed a novel approach to construct virtual patient cohorts that better mirror real individuals with type 1 diabetes, potentially enhancing computer-based testing of glucose control systems and insulin management strategies. Researchers at Scientific Reports, part of the Nature…
Recent reviews highlight that while AI models show promise in early diabetes detection, issues with data diversity, validation, and bias threaten their clinical reliability, emphasising the need for rigorous development and real-world testing. Machine learning is increasingly being tested as…
Jessie Inchauspé, known as the ‘Glucose Goddess’, advocates simple dietary adjustments like meal timing and food order to curb glucose spikes, potentially reducing the risk of chronic health issues linked to high blood sugar. Jessie Inchauspé, the biochemist and author…
A new European research initiative aims to evaluate the real-world implementation of a smartphone-based coaching programme designed to help pregnant women at risk of gestational diabetes, focusing on integration across diverse health systems and establishing a practical toolkit for widespread…
Regular intake of sugary sodas is increasingly associated with obesity, heart disease, dental issues, and blood sugar spikes, prompting calls for moderation and healthier alternatives amid growing public health concerns. Drinking soda every day may seem harmless in the moment,…
A breakthrough in wearable tech as UC San Diego researchers create a ring that tracks multiple chemical markers from sweat, promising more personalised health insights beyond traditional smartwatches. A team at the University of California, San Diego has developed a…
Syai Health unveils the Ultra CGM, a discreet 14-day glucose monitor integrated with AI-powered software to enhance user experience and decision-making for people with diabetes in South Africa. Syai Health is seeking to win over people with diabetes with a…
The US Food and Drug Administration has expanded the use of Eli Lilly’s tirzepatide, or Mounjaro, to include lowering the risk of major cardiovascular events in adults with high-risk type 2 diabetes, based on a significant clinical trial demonstrating its…
Recent research uncovers mechanistic links between high blood sugar, insulin resistance, and pancreatic cancer, showing how metabolic dysfunction may promote tumour formation and metastasis through distinct biological pathways. New research is sharpening understanding of why high blood sugar and insulin…
The Met-HeFT trial reveals that metformin does not significantly lower the risk of major cardiovascular events in patients with heart failure and reduced ejection fraction, challenging previous observational data suggesting potential benefits. Metformin does not appear to reduce the risk…
